Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medicinal cannabis crossover trial for chronic low back pain in opioid-dependent adults
ACTRN12626000153314Phase 2Not yet recruiting
- Sponsor
- The University of Sydney
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dronabinol and cannabidiol in chronic low back pain (CLBP), sponsored by The University of Sydney. Primary endpoint: Pain severity. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
dronabinolcannabidiol
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on ACTRN12626000153314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000153314.